Skip to main content

Advertisement

Fig. 1 | Cell & Bioscience

Fig. 1

From: Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

Fig. 1

HQP1351 inhibits colony formation, cell migration and invasion. a GIST 430 cells were incubated with 0.3 μM imatinib, ponatinib or HQP1351 for 14 days, and then stained with 0.5% crystal violet to count the number of cell colony. b Near-confluent GIST 430 cells were slashed and further incubated with 0.3 μM imatinib, ponatinib or HQP1351 for 5 days. The average extent of wound closure was evaluated on day 5. c GIST 430 cells were seeded on the upper chamber of a Transwell plate and incubated with 0.3 μM imatinib, ponatinib or HQP1351 for 24 h. The cells that migrated to the lower side of the wells were stained with 0.1% crystal violet and counted. *P < 0.05, ***P < 0.001, ****P < 0.0001, n = 3

Back to article page